CG Structure · 2025
In this section19 topics
- Board Composition8 items
- Board of Directors1 item
- Board Meetings & Remuneration5 items
- Balance of Power Between the Board and Management5 items
- Board Roles, Duties and Charter2 items
- Other Board Governance Matters1 item
- Audit Committee5 items
- Executive Committee5 items
- Other Subcommittees1 item
- Executives1 item
- Executive Remuneration5 items
- Remuneration Policy4 items
- Employees2 items
- Provident Fund4 items
- Policy for Employees Not in the Provident Fund5 items
- Auditors and Audit Fees2 items
- Company Secretary and Other Assigned Persons4 items
- Investor Relations Contact2 items
- Representatives in Thailand (Foreign Companies)1 item
Board Composition
Total Number of Directors
9
Male Directors
6
Female Directors
3
Independent Directors
4
Non-executive Directors
6
Non-executive Directors Who Are Not Independent
2
Executive Directors
3
Total Board Meetings Held
6
Board of Directors
Directors
| Title | Title — Please Specify | First Name | Last Name | Gender | Year of Birth | Nationality | Resident in Thailand? | Position | Executive or Non-executive | Independent Director? | Director Type | Appointment Date | Authorised to Sign? | Related to Another Director or Executive? | Any Legal Violation in the Past 5 Years? | Highest Education | Field of Study | Field of Study — Please Specify | Skills & Expertise | Director Training | Attended Director Training? | Director Accreditation Program (DAP)? | Director Certification Program (DCP)? | Board Meetings Held | Board Meetings Attended | AGMs Held | AGMs Attended | Meeting Allowance (Baht) | Other Remuneration (Baht) | Total Remuneration (Baht) | Non-monetary Remuneration | Shares Held | Shareholding (%) | Shares Held by Related Persons (s.59) | Shareholding by Related Persons (s.59, %) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| other | Clinical Professor Emeritus, MD. | UDOM | KACHINTORN | M | 1,954 | 643 · Description: Thailand | Y | Chairman of the board | Non-executive | Y | Existing director | 2019-12-17T00:00 | N | N | N | Doctoral degree | Medicine | 134 · Description: Health Care Services · 265 · Description: Governance/ Compliance · 117 · Description: Personal Products & Pharmaceuticals · 164 · Description: Strategic Management · 158 · Description: Corporate Management | N | Y | Y | 6 | 6 | 1 | 1 | 120,000 | 360,000 | 480,000 | 0 | 0 | 0 | 0 | 0 | ||
| other | Dr. | TRINNAWAT | THANITNITHIPHAN | M | 1,970 | 643 · Description: Thailand | Y | Director | Executive | Existing director | 2014-02-01T00:00 | Y | N | N | Doctoral degree | other | Organizational Development | 164 · Description: Strategic Management · 158 · Description: Corporate Management · 142 · Description: Marketing · 117 · Description: Personal Products & Pharmaceuticals · 1683 · Description: Business Administration | 2025 · Description: Rule of Law for Democracy Program, Class 13, Constitutional Court Academy · 2025 · Description: Digital CEO Program, Class 9, Ministry of Digital Economy and Society · 2024 · Description: Climate Action Leader Program, Class 3, Ministry of Natural Resources and Environment | Y | N | Y | 6 | 6 | 1 | 1 | 0 | 0 | 0 | 0 | 193,774,067 | 32.01 | 0 | 0 | |
| Ms. | NAPAPORN | DECHAKARAT | F | 1,975 | 643 · Description: Thailand | Y | Director | Executive | Existing director | 2017-06-14T00:00 | Y | N | N | Bachelor's degree | Business Administration | 165 · Description: Risk Management · 148 · Description: Procurement · 142 · Description: Marketing · 117 · Description: Personal Products & Pharmaceuticals · 140 · Description: Information & Communication Technology | N | Y | N | 6 | 6 | 1 | 1 | 0 | 0 | 0 | 0 | 234 | 0 | 0 | 0 | ||||
| other | Professor Dr. | SANSANEE | CHAIYAROJ | F | 1,962 | 643 · Description: Thailand | Y | Director | Non-executive | Y | Existing director | 2020-08-01T00:00 | N | N | N | Doctoral degree | other | immunobiology | 165 · Description: Risk Management · 134 · Description: Health Care Services · 265 · Description: Governance/ Compliance · 117 · Description: Personal Products & Pharmaceuticals · 164 · Description: Strategic Management | 2025 · Description: Audit Committee Seminar by EY Office Limited | Y | N | Y | 6 | 6 | 1 | 1 | 90,000 | 240,000 | 330,000 | 0 | 0 | 0 | 0 | 0 |
| Mr. | KAMTORN | SILA-ON | M | 1,970 | 643 · Description: Thailand | Y | Director | Non-executive | Y | Continuing director (Full term of directorship and being re-appointed as a director) | 2021-02-08T00:00 | N | N | N | Master's degree | Business Administration | 144 · Description: Finance · 143 · Description: Accounting · 265 · Description: Governance/ Compliance · 164 · Description: Strategic Management · 117 · Description: Personal Products & Pharmaceuticals | 2025 · Description: Audit Committee Seminar by EY Office Limited · 2025 · Description: Hot Issue for Directors, The Evolving Role of Audit Committee in Fostering Trust and Transparency by SET | Y | N | Y | 6 | 6 | 1 | 1 | 90,000 | 240,000 | 330,000 | 0 | 0 | 0 | 0 | 0 | ||
| other | Dr. | PAO | SRIPRASERTSUK | M | 1,975 | 643 · Description: Thailand | Y | Director | Non-executive | Y | Continuing director (Full term of directorship and being re-appointed as a director) | 2021-11-10T00:00 | N | N | N | Doctoral degree | Computer Science | 150 · Description: IT Management · 265 · Description: Governance/ Compliance · 164 · Description: Strategic Management · 117 · Description: Personal Products & Pharmaceuticals | N | Y | N | 6 | 6 | 1 | 1 | 90,000 | 240,000 | 330,000 | 0 | 0 | 0 | 0 | 0 | ||
| Mrs. | APIMON | POSRI | F | 1,970 | 643 · Description: Thailand | Y | Director | Executive | Continuing director (Full term of directorship and being re-appointed as a director) | 2022-07-20T00:00 | Y | N | N | Bachelor's degree | Business Administration | 146 · Description: Human Resource Management · 150 · Description: IT Management · 117 · Description: Personal Products & Pharmaceuticals · 145 · Description: Corporate Social Responsibility · 158 · Description: Corporate Management | N | Y | N | 6 | 6 | 1 | 1 | 0 | 0 | 0 | 0 | 234 | 0 | 0 | 0 | ||||
| Mr. | NAT | ATIVITAVAS | M | 1,974 | 643 · Description: Thailand | Y | Director | Non-executive | N | Existing director | 2022-08-10T00:00 | N | N | N | Doctoral degree | Engineering | 164 · Description: Strategic Management · 142 · Description: Marketing · 165 · Description: Risk Management · 158 · Description: Corporate Management · 117 · Description: Personal Products & Pharmaceuticals | N | Y | N | 6 | 6 | 1 | 1 | 90,000 | 240,000 | 330,000 | 0 | 0 | 0 | 0 | 0 | |||
| Mr. | YUTTANA | SUWANNACHOT | M | 1,970 | 643 · Description: Thailand | Y | Director | Non-executive | N | Existing director | 2023-02-27T00:00 | N | N | N | Doctoral degree | Science | 164 · Description: Strategic Management · 158 · Description: Corporate Management · 265 · Description: Governance/ Compliance · 117 · Description: Personal Products & Pharmaceuticals | N | Y | N | 6 | 6 | 1 | 1 | 90,000 | 240,000 | 330,000 | 0 | 0 | 0 | 0 | 0 |
Board Meetings & Remuneration
Date of the Annual General Meeting
2015-04-28T00:00
Was an Extraordinary General Meeting Held?
No
Board Meeting Allowance (Baht)
570000.0
Other Board Remuneration (Baht)
1560000.0
Total Board Remuneration (Baht)
2130000.0
Balance of Power Between the Board and Management
Are There Measures Balancing the Board's and Management's Power?
Yes
Measures Balancing the Board's and Management's Power
The Chairman of the Board of Directors must not be the same person as the Chief Executive Officer to ensure a balance of power. The Chairman of the Board of Directors plays a leading role in the Board of Directors.
(A) Set the agenda for board meetings in consultation with the Chief Executive Officer and have measures in place to ensure that important matters are included in the meeting agenda.
(B) Allocate sufficient time for management to present matters and for directors to thoroughly discuss key issues.
(C) Encourage directors to exercise their discretion and express their opinions independently.
Methods Used to Balance Power
| Method |
|---|
| Appointment of an independent director Participate in determining the meeting agenda for the committee |
Link to the Power-balancing Policy
https://investor.interpharma.co.th/storage/downloads/corporate-governance/20250324-ip-cg-policy-en.pdf
Page in the Report
6
Board Roles, Duties and Charter
Does the Company Have a Board Charter?
Yes
Content of the Board Charter
The Company has established the Board of Directors Charter to clearly define the roles, duties, responsibilities, and authority of the Board of Directors in order to ensure that the Board performs its duties efficiently, transparently, and in accordance with the principles of good corporate governance. The key elements of the Board of Directors Charter are summarized as follows:
1. Structure and Composition of the Board of Directors
The Board of Directors shall consist of independent directors representing at least one-third of the total number of directors. Independent directors must possess the qualifications as prescribed by the Capital Market Supervisory Board. The Chairman of the Board should be an independent director and must not be the same person as the Chief Executive Officer.
2. Qualifications of Directors
The Board of Directors comprises individuals with knowledge, expertise, and experience that are beneficial to the Company’s business operations.
3. Term of Office of Directors
Independent directors may serve a maximum consecutive term of nine years. In addition, directors may hold directorships in no more than five listed companies.
4. Roles, Duties, and Responsibilities of the Board of Directors
The Board of Directors is responsible for determining the Company’s policies, vision, strategies, and business directions, as well as overseeing the management’s operations to ensure alignment with the established policies. The Board performs its duties with responsibility, due care, and integrity for the best interests of the Company and its shareholders as a whole.
5. Board Meetings and Quorum
The Board of Directors shall convene at least six meetings per year to consider and monitor the Company’s operating performance as well as to deliberate on significant matters relating to the Company’s business operations. Relevant meeting materials and supporting documents are provided to directors at least five working days in advance of the meeting date. For a Board meeting to constitute a quorum at the time a resolution is passed, at least two-thirds of the total number of directors must be present.
6. Performance Evaluation of the Board of Directors
The Company requires an annual performance evaluation of the Board of Directors, both collectively and individually, in order to enhance the effectiveness of the Board in overseeing the Company’s corporate governance.
Other Board Governance Matters
Board Governance Practices
| Practice | Yes / No |
|---|---|
| The chairman of the board and the highest-ranking executive are from the same person | N |
| The chairman of the board is an independent director | Y |
| The chairman of the board and the highest-ranking executive are from the same family | N |
| Chairman is a member of the executive board or taskforce | N |
| The company appoints at least one independent director to determine the agenda of the board of directors’ meeting | N |
Audit Committee
Audit Committee Charter
| Roles, Duties and Responsibilities | Type of Subcommittee |
|---|---|
The Audit Committee has roles, duties, and responsibilities according to the charter:
1. Review the Company's financial reporting to ensure it is accurate and sufficient.
2. Review the Company's internal control system and internal audit system to ensure that they are suitable and effective. Consider the independence of the internal audit unit as well as approve the appointment, transfer, or termination of the head of the internal audit unit or any other unit responsible for internal auditing.
3. Review the Company's compliance with the laws on securities and stock exchange, the regulations of the Stock Exchange of Thailand, and laws related to the Company's business.
4. Consider, select, and nominate an independent person to be the Company's auditor and propose such a person's remuneration. Attend a meeting with the auditor without the participation of the management division at least once a year.
5. Consider related party transactions or transactions that may have conflicts of interest in accordance with the laws and regulations of the Stock Exchange of Thailand to ensure that such transactions are reasonable and in the best interest of the Company.
6. Prepare a report of the Audit Committee to be disclosed in the Company's annual report. The report must be signed by the chairman of the Audit Committee and contain at least the following information:
(a) Opinions on the accuracy, completeness, and reliability of the Company's financial reports
(b) Opinions on the adequacy of the Company's internal control system
(c) Opinions on compliance with the Securities and Exchange Act, the SET requirements, or other laws related to the Company's business.
(d) Opinions on the suitability of an auditor
(e) Opinions on transactions that may have conflicts of interest
(f) The number of Audit Committee meetings and the attendance at such meetings by each member of the Audit Committee
(g) Opinions or overall observations received by the Audit Committee from performing their duties in accordance with the charter.
(h) Other items that shareholders and general investors should know under the scope of duties and responsibilities assigned by the Board of Directors
7. Perform any other act as assigned by the Board of Directors with the approval of the Audit Committee.
| 3091 · Description: Audit of financial statements and internal controls |
Audit Committee Members
| Title | Title — Please Specify | First Name | Last Name | Position | Gender | Year of Birth | Nationality | Resident in Thailand? | Appointment Date | Highest Education | Field of Study | Field of Study — Please Specify | Has Accounting or Financial Expertise? | Skills & Expertise | Meetings Held | Meetings Attended | Meeting Allowance (Baht) | Other Remuneration (Baht) | Total Remuneration (Baht) | Non-monetary Remuneration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mr. | KAMTORN | SILA-ON | Chairman of the audit committee | M | 1,970 | 643 · Description: Thailand | Y | 2021-02-08T00:00 | Master's degree | Business Administration | Y | 144 · Description: Finance · 143 · Description: Accounting · 265 · Description: Governance/ Compliance · 164 · Description: Strategic Management · 117 · Description: Personal Products & Pharmaceuticals | 4 | 4 | 90,000 | 0 | 90,000 | 0 | ||
| other | Dr. | PAO | SRIPRASERTSUK | Audit committee | M | 1,975 | 643 · Description: Thailand | Y | 2021-11-10T00:00 | Doctoral degree | Computer Science | N | 150 · Description: IT Management · 265 · Description: Governance/ Compliance · 164 · Description: Strategic Management · 117 · Description: Personal Products & Pharmaceuticals | 4 | 4 | 60,000 | 0 | 60,000 | 0 | |
| other | Professor Dr. | SANSANEE | CHAIYAROJ | Audit committee | F | 1,962 | 643 · Description: Thailand | Y | 2020-08-01T00:00 | Doctoral degree | other | immunobiology | N | 165 · Description: Risk Management · 134 · Description: Health Care Services · 265 · Description: Governance/ Compliance · 117 · Description: Personal Products & Pharmaceuticals · 164 · Description: Strategic Management | 4 | 4 | 60,000 | 0 | 60,000 | 0 |
Audit Committee — Meeting Allowance (Baht)
210000.0
Audit Committee — Other Remuneration (Baht)
0.0
Audit Committee — Total Remuneration (Baht)
210000.0
Executive Committee
Executive Committee Charter
| Roles, Duties and Responsibilities | Type of Subcommittee |
|---|---|
1. Present the goal, policy, business plan, including operations strategy, the Company’s annual budget, business expansion, financial plan determination, and human resources administration together with considering and screening suggestions from the management division to propose to the Board of Directors for approval.
2. Control and supervise the operations, and monitor the Company’s performance to be in accordance with the set policies, goals, strategies, business plans, and budgets approved by the Board of Directors to be effective, as well as providing management suggestions to top executives.
3. Consider and approve the operations with normal business transactions as well as the operations supporting the normal business of the Company with general trade conditions in the amount of each item not exceeding 100 million Baht but not exceeding the budget as approved by the Board of Directors or as approved by the Board of Directors in the principles. It must be conducted under the regulations of The Office of the Securities and Exchange Commission including the Stock Exchange of Thailand regarding the related transactions and the transactions of the disposition of assets.
4. Consider the proposed interim dividend payment or the annual dividend payment to propose to the Board of Directors for approval or agreement for proposing to the Shareholders’ Meeting depending on the case.
5. Consider and approve any related party transactions that are not regarded as stakeholders, which are the transactions with trade agreements in the same manner that a person of ordinary prudence would do with general counterparties in the same situation with the trade bargaining power that is free from influence between the Company and its subsidiaries and directors, executives, or related persons as well as proceeding in any necessary steps related to doing such transactions. This includes considering to assign any individuals to perform such matters under the scope of authorization from time to time. The Executive Committee shall report such transactions with significant high value in the Board of Directors Meeting every quarter or as the wishes of the Board of Directors.
6. Appoint executive directors or managing directors or one or more other persons to handle the Company operations on behalf of the Executive Committee under the control and supervision of the Executive Committee within a period as the committee sees appropriate. The Executive Committee may also terminate, void, change, or modify the delegation when deemed appropriate.
7. Authorize to appoint the working group to consider any matters that the Executive Committee deems appropriate.
8. Authorize to appoint the consultants in various fields necessary for the operations of the Company within the budget approved by the Board of Directors each year.
Such appointment must be made in writing or recorded as a resolution of the Executive Committee, including clearly specifying the scope of duties and duration (if any) of the assignees.
In addition, the delegation must not be the delegation that makes the person authorized to consider and approve the transactions with possible conflicts of interest, stakes, or any other conflicts of interest with the Company unless it is an approval of the transaction which is in accordance with the regulations and criteria that the Board of Directors considered and approved, or an ordinary business transaction with general trading conditions. Such transactions must be conducted under the regulations, conditions, and procedures regarding the related party transactions and the transactions on acquisition or disposition of assets of the Company according to the notifications of the Capital Market Supervisory Board and/or any other notifications of relevant agencies.
9. Consider and screen every type of work that needs to propose to the Board of Directors Meeting unless it is the work under the authority and responsibility and/or is the authority of the other sub-committees of the Company to consider and screen to directly propose with the Board of Directors.
10. Review and revise the charter of the Executive Committee every year.
11. Perform any other duties as assign by the Board of Directors.
In this regard, it is authorized to adjust the scope of the approval authority of the Board of Directors according to item (1) - (11) for appropriateness and in accordance with the laws enforced at the time.
| 3097 · Other name: To supervise the Company’s operations and monitor its performance to ensure compliance with the established policies, strategies, plans, and objectives. · Description: Others |
Executive Committee Members
| Title | Title — Please Specify | First Name | Last Name | Position | Gender | Year of Birth | Nationality | Resident in Thailand? | Appointment Date | Highest Education | Field of Study | Field of Study — Please Specify | Meetings Held | Meetings Attended | Meeting Allowance (Baht) | Other Remuneration (Baht) | Total Remuneration (Baht) | Non-monetary Remuneration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| other | Dr. | TRINNAWAT | THANITNITHIPHAN | Chairman of the executive committee | M | 1,970 | 643 · Description: Thailand | Y | 2021-08-12T00:00 | Doctoral degree | other | Organizational Development | 6 | 5 | 0 | 0 | 0 | 0 |
| Ms. | NAPAPORN | DECHAKARAT | Member of the executive committee | F | 1,975 | 643 · Description: Thailand | Y | 2021-08-12T00:00 | Bachelor's degree | Business Administration | 6 | 6 | 0 | 0 | 0 | 0 | ||
| Mrs. | APIMON | POSRI | Member of the executive committee | F | 1,970 | 643 · Description: Thailand | Y | 2021-08-12T00:00 | Bachelor's degree | Business Administration | 6 | 6 | 0 | 0 | 0 | 0 | ||
| Mr. | Dranun | Jamsai | Member of the executive committee | M | 1,983 | 643 · Description: Thailand | Y | 2022-08-09T00:00 | Master's degree | Economics | 6 | 6 | 0 | 0 | 0 | 0 |
Executive Committee — Meeting Allowance (Baht)
0.0
Executive Committee — Other Remuneration (Baht)
0.0
Executive Committee — Total Remuneration (Baht)
0.0
Other Subcommittees
Other Subcommittees
| Subcommittee Name | Type of Subcommittee | Roles, Duties and Responsibilities | Meetings Held | Subcommittee Remuneration | Members |
|---|---|---|---|---|---|
| Nomination and Remuneration Committee | 3093 · Description: Director and executive nomination · 3094 · Description: Remuneration | • Nomination
1. Consider setting criteria and methods for recruiting directors and top executives.
2. Consider the structure, size, and composition of the Board of Directors and subcommittees to be appropriate with the Company's strategy and the changing situation.
3. Consider recruiting, selecting, and nominating appropriate persons to serve as directors who have completed their terms and/or have vacancies and/or additional appointments, taking into account the diversity of knowledge, expertise, skills, and experiences that are beneficial to the Company's business operations and dedication.
4. Encourage the Company to provide opportunities for minority shareholders to nominate candidates for nomination as company directors.
5. Consider selecting qualified directors to serve as members of subcommittees to propose appointments to the Board of Directors as appropriate or when there is a vacancy.
6. Consider the qualifications of the highest executives suitable for the management of the Company's business, including recruiting, selecting, and nominating suitable persons for such positions upon vacancies by covering education, experience, knowledge, and expertise as well as taking environmental factors and business competition into consideration.
7. Review the succession plan for the Company's highest management positions regularly, along with the list of candidates to be considered for succession, and propose to the Board of Directors an appointment when the position becomes vacant.
8. Perform any other operations related to recruitment as assigned by the Board of Directors.
• Remuneration
1. Ensure that directors and high-ranking executives of the Company receive compensation that is appropriate for their duties and responsibilities towards the Company. Directors who are assigned more duties and responsibilities should receive remuneration appropriate to the duties and responsibilities assigned to them.
2. Determine necessary and appropriate remuneration, both monetary and non-monetary, of directors by linking remuneration with duties, responsibilities, and the overall performance of the Company, comparing with companies in similar businesses, and estimating the benefits expected from directors to be able to motivate and retain capable, qualified, and potential directors. This will be proposed to the Board of Directors for approval before being presented to the Shareholders’ Meeting for approval.
3. Consider approving and reviewing the compensation structure for the top executives of the Company, as well as assessing the year's performance and considering adjusting the appropriate remuneration rate for the Company's top executives to propose to the Board of Directors for approval.
4. Acknowledge the criteria and guidelines for allocating performance bonuses, and adjusting annual salary for employees and executives upwards by considering various factors such as the Company's performance in the same industry or similar industries, etc. to be prepared under the annual budget framework and compensation management principles that the total compensation is as specified by the Company.
5. Perform any other tasks related to remuneration as assigned by the Board of Directors.
| 2 | 50000.0 · Meeting allowance: 50000.0 · Other remuneration: 0.0 | 260 · Last name: SILA-ON · Position: 37 · First name: KAMTORN · Total meeting: 2 · Meeting allowance: 30000.0 · Other remuneration: 0.0 · Total remuneration: 30000.0 · Total meeting attendance: 2 · Non monetary remuneration: 0 · 263 · Last name: SRIPRASERTSUK · Position: 39 · First name: PAO · Total meeting: 2 · Title other name: Dr. · Meeting allowance: 20000.0 · Other remuneration: 0.0 · Total remuneration: 20000.0 · Total meeting attendance: 2 · Non monetary remuneration: 0 · 263 · Last name: THANITNITHIPHAN · Position: 39 · First name: TRINNAWAT · Total meeting: 2 · Title other name: Dr. · Meeting allowance: 0.0 · Other remuneration: 0.0 · Total remuneration: 0.0 · Total meeting attendance: 2 · Non monetary remuneration: 0 |
| Corporate Governance and Sustainable Development Committee | 3095 · Description: Corporate governance · 3096 · Description: Sustainability development · 3169 · Description: Climate-related risks and opportunities governance | 1. Consider, review, and present to the Board of Directors for approval good corporate governance policy, business ethics, social responsibility policy, environment policy, company sustainable development policy, and any other policies and guidelines that will support the Company's operations in accordance with good governance to create transparency, fairness, and support sustainable growth of the Company.
2. Supervise the management to implement the policies and guidelines in Item 1 to continuously develop the Company. Such policies and guidelines must be in line with and suitable for the Company's business, be recommendations of regulatory agencies, or be relevant to and comparable to international standards.
3. Follow up and review various work systems within the organization in accordance with the code of conduct and best practices as defined.
4. Follow up and give orders in the event that the operations of the management and employees have issues that do not comply with the policies and guidelines that have been laid down.
5. Follow up and report the performance of the organization according to the good corporate governance policy and other related policies to the Board of Directors and external organizations as appropriate.
6. Supervise to create the anti-corruption policy that is appropriate and adequate for business operations.
7. Sustainable development in business operations is conducted by adhering to the responsibility to all stakeholders for sustainable mutual benefits which consisted of economic, social, and environmental aspects under good corporate governance principles.
8. Give advice and support to the chief executive officer in relation to the development of sustainability operations.
9. Have the authority to invite executives or any persons related to the Company to provide a comment, attend the meeting, or provide relevant information.
10. Perform other duties as assigned by the Board of Directors.
| 2 | 90000.0 · Meeting allowance: 90000.0 · Other remuneration: 0.0 | 263 · Last name: KACHINTORN · Position: 37 · First name: UDOM · Total meeting: 2 · Title other name: Clinical Professor Emeritus, MD. · Meeting allowance: 30000.0 · Other remuneration: 0.0 · Total remuneration: 30000.0 · Total meeting attendance: 2 · Non monetary remuneration: 0 · 263 · Last name: CHAIYAROJ · Position: 39 · First name: SANSANEE · Total meeting: 2 · Title other name: Professor Dr. · Meeting allowance: 20000.0 · Other remuneration: 0.0 · Total remuneration: 20000.0 · Total meeting attendance: 2 · Non monetary remuneration: 0 · 260 · Last name: SILA-ON · Position: 39 · First name: KAMTORN · Total meeting: 2 · Meeting allowance: 20000.0 · Other remuneration: 0.0 · Total remuneration: 20000.0 · Total meeting attendance: 2 · Non monetary remuneration: 0 · 263 · Last name: SRIPRASERTSUK · Position: 39 · First name: PAO · Total meeting: 2 · Title other name: Dr. · Meeting allowance: 20000.0 · Other remuneration: 0.0 · Total remuneration: 20000.0 · Total meeting attendance: 2 · Non monetary remuneration: 0 |
| Risk Management Committee | 3092 · Description: Risk management | 1. Assign the risk management policy, risk appetite, and risk tolerance to present the risk management policy to the Board of Directors for approval. It needs to cover various types of risks that are important from both inside and outside the corporate.
2. Plan the strategies and actions for the risk management to correspond with the risk management policy. It must be able to assess, monitor, and supervise the overall risk management system or process to be at the appropriate and acceptable level.
3. Control, follow up, inspect, evaluate the risk management, and supervise the Company to manage and operate under the risk management policy set by the Company together with complying with the set regulations.
4. Review the risk management report and execute to ensure that the corporate has the appropriate risk management with sufficient policy and system, including the system effectiveness and execution of the set policy.
5. Consider to improve, revise, and express opinions on the risk management policy, plan, and process to propose to the Board of Directors for consideration and approval.
6. Report the status of the Company’s risks, the guidelines that need to be improved, and the operational results to the Board of Directors every quarter.
7. Supervise, support, encourage cooperation in the Company’s risk management, and continuously review the adequacy of the risk management policy and system for the risk management to operate effectively.
8. Authorize to establish the working group to obligate the risk management and report to the Audit Committee.
9. Provide advice to the Board of Directors and the management division about the risk management.
10. Report to the Board of Directors Meeting about important risk records and the risk status assessment of the risk management and the impact that will occur in the operations, including how to prevent and what needs to be improved. In case of a significant impact on the Company, it must report to the Board of Directors as soon as possible.
11. Perform any other tasks assigned by the Board of Directors.
12. Review the charter of the Risk Management Committee once a year or as necessary and appropriate.
| 2 | 30000.0 · Meeting allowance: 30000.0 · Other remuneration: 0.0 | 263 · Last name: CHAIYAROJ · Position: 37 · First name: SANSANEE · Total meeting: 2 · Title other name: Professor Dr. · Meeting allowance: 30000.0 · Other remuneration: 0.0 · Total remuneration: 30000.0 · Total meeting attendance: 2 · Non monetary remuneration: 0 · 263 · Last name: THANITNITHIPHAN · Position: 39 · First name: TRINNAWAT · Total meeting: 2 · Title other name: Dr. · Meeting allowance: 0.0 · Other remuneration: 0.0 · Total remuneration: 0.0 · Total meeting attendance: 2 · Non monetary remuneration: 0 · 261 · Last name: DECHAKARAT · Position: 39 · First name: NAPAPORN · Total meeting: 2 · Meeting allowance: 0.0 · Other remuneration: 0.0 · Total remuneration: 0.0 · Total meeting attendance: 2 · Non monetary remuneration: 0 |
Executives
Executives
| Title | Title — Please Specify | First Name | Last Name | Position | Gender | Year of Birth | Nationality | Resident in Thailand? | Appointment Date | Highest Education | Field of Study | Field of Study — Please Specify | Skills & Expertise | Is the Highest-ranking Executive? | Is the Highest-ranking Accounting or Finance Officer? | Directly Responsible for Accounting? | Appointed After the End of the Fiscal Year? |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| other | Dr. | TRINNAWAT | THANITNITHIPHAN | CHIEF EXECUTIVE OFFICER | M | 1,970 | 643 · Description: Thailand | Y | 2014-02-01T00:00 | Doctoral degree | other | Organizational Development | 164 · Description: Strategic Management · 158 · Description: Corporate Management · 142 · Description: Marketing · 117 · Description: Personal Products & Pharmaceuticals · 1683 · Description: Business Administration | Y | N | N | N |
| Ms. | NAPAPORN | DECHAKARAT | Chief Operating Officer | F | 1,975 | 643 · Description: Thailand | Y | 2017-06-14T00:00 | Bachelor's degree | Business Administration | 165 · Description: Risk Management · 148 · Description: Procurement · 142 · Description: Marketing · 117 · Description: Personal Products & Pharmaceuticals · 140 · Description: Information & Communication Technology | N | N | N | N | ||
| Mrs. | APIMON | POSRI | Human Resources Director | F | 1,970 | 643 · Description: Thailand | Y | 2020-07-01T00:00 | Bachelor's degree | Business Administration | 146 · Description: Human Resource Management · 150 · Description: IT Management · 117 · Description: Personal Products & Pharmaceuticals · 145 · Description: Corporate Social Responsibility · 158 · Description: Corporate Management | N | N | N | N | ||
| Ms. | Chatkaew | Krudkosol | Acting Chief Financial & Accounting | F | 1,969 | 643 · Description: Thailand | Y | 2023-06-23T00:00 | Bachelor's degree | Accounting | 168 · Description: Budgeting · 1683 · Description: Business Administration · 143 · Description: Accounting · 144 · Description: Finance · 117 · Description: Personal Products & Pharmaceuticals | N | Y | N | N |
Executive Remuneration
Monetary Remuneration — Description
The Company paid monetary compensation to four executives, consisting of salaries and special remuneration.
Monetary Remuneration
| Metric | Current Year | Previous Year | Two Years Ago |
|---|---|---|---|
| Total remuneration of executive directors and executives (baht) | 19,836,510 | 18,440,000 | 20,480,000 |
| Total remuneration of executive directors (baht) | 0 | 0 | 0 |
| Total remuneration of executives (baht) | 19,836,510 | 18,440,000 | 20,480,000 |
Other Remuneration — Description
The Company has established a provident fund for its executives, to which the Company contributes at a rate of 5% of salary. In 2025, the Company made provident fund contributions for four executives.
Other Remuneration
| Metric | Current Year | Previous Year | Two Years Ago |
|---|---|---|---|
| Company’s contribution to provident fund for executive directors and executives (Baht) | 920,490 | 908,798 | 874,787 |
| Employee Stock Ownership Plan (ESOP) | 0 | 0 | 0 |
| Employee Joint Investment Program (EJIP) | 0 | 0 | 0 |
Remuneration or Benefits Payable to Executives
| Metric | Amount (Baht) |
|---|---|
| Outstanding remuneration or benefits of executive directors and executives in the past year (baht) | 0 |
| Estimated remuneration of executive directors and executives in the current year (baht) | 0 |
Remuneration Policy
Executive Remuneration Policy
The Company has established a remuneration policy for top executives. The Nomination and Remuneration Committee shall consider the remuneration of the chief executive officer by considering the Company's duties, responsibilities, results, and performance. The Company shall determine the remuneration structure that is an incentive for the chief executive officer and top executives to work in line with the objectives and main goals of the organization and be consistent with the long-term benefits of the business. This includes considering the appropriate remuneration proportion of salary, short-term performance such as bonuses, and long-term performance such as the Employee Stock Option Plan. In this regard, the remuneration rate of top executives is the rate that can be compared with other businesses in the same industry.
Opinion of the Board and the Remuneration Committee
The Board of Directors and the Nomination and Remuneration Committee considered the remuneration of the Company’s top executives by taking into account their roles, duties, and responsibilities, performance, and the Company’s operating results. The executive remuneration, comprising salaries and special remuneration, was determined in alignment with the performance of each executive and the Company’s operating results, at rates comparable to those of businesses within the same industry. The Board is of the opinion that the top executive remuneration of the Company is reasonable and appropriate.
Link to the Remuneration Policy
https://investor.interpharma.co.th/storage/downloads/corporate-governance/20230323-ip-remuneration-policy-for-directors-senior-executives-th.pdf
Page in the Report
1
Employees
Employees by Department
| Department | Employees |
|---|---|
| Inter Pharma Public Company Limited (Head Office and Sales Division_ | 73 |
| Inter Pharma Public Company Limited (Ayutthaya Manufacturing Facility) | 94 |
| Inter Vetta Company Limited (Pet Healthcare Products Business) | 27 |
| Modern Phama Company Limited (Samut Prakan Manufacturing Plant) | 128 |
| Drug Care Company Limited (Pharmacy Business) | 186 |
| Nakhonpat Inter Company Limited (Hospital Business) | 194 |
| Interpharma Madtech Company Limited (Medical Devices Business) | 61 |
Any Significant Change in Headcount in the Past 3 Years?
No
Provident Fund
Does the Company Have a Provident Fund?
Yes
Provident Fund Policy
The Company has established a provident fund under the management of TISCO Asset Management Co., Ltd., with the objective of enhancing employee morale and encouraging long-term employment. The Company has contributed to the provident fund since July 2016.
The Company has adopted an investment policy that allows employees to select investment plans based on their risk appetite. The investment options are divided into fixed income (MRT-F) and equity (MRT-E) policies, comprising five investment plans: F100, F90E10, F80E20, F70E30, and F60E40.
In selecting the fund manager, the Company considers factors such as the management company’s past performance, investment outlook, organizational structure, and operational systems to ensure efficient fund management aligned with employees’ investment objectives.
Does the Fund Committee Follow the I Code?
Yes
Contribution Method and Rate
The Company allows employees who are members of the provident fund to select their contribution rates at 5%, 10%, or 15% of their salary. Members may change their contribution rate once per year in December by submitting a written notification to the fund committee, with such changes becoming effective in the following month. The Company contributes to the provident fund at a rate of 5% of the employee’s salary.
Policy for Employees Not in the Provident Fund
Automatic Enrolment
No
Encouraging Retirement Saving
No
Providing Investment Information
Yes
Providing Investment Information — Details
The Company recognizes the importance of promoting long-term financial planning among its employees and executives. Therefore, the Company provides information and guidance on selecting appropriate investment policies under the provident fund, taking into consideration each individual’s risk tolerance, age, and financial objectives.
The Company communicates information regarding the provident fund’s investment policies through various channels, such as fund information documents, internal communication platforms, and information provided by the fund management company. This enables employees and executives to better understand the investment characteristics, risk levels, and expected returns of each investment policy before making their investment decisions.
In addition, the Company encourages employees and executives to periodically review and adjust their provident fund investment policies, as appropriate, to ensure alignment with their life stage, financial obligations, and long-term retirement savings goals.
Other Measures
No
Auditors and Audit Fees
How Audit Fees Are Reported
TOTAL
Company Auditor and Fees
| Audit Firm | Address | Sub-district | District | Province | Postcode | Fax | Auditors | Audit Fee (Baht) | Any Non-audit Fee? | Type of Non-audit Service | Non-audit Service Details | Non-audit Fee (Baht) | Amount Paid During the Year (Baht) | Amount Payable in Future (Baht) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EY OFFICE LIMITED | NO. 1875 ONE BANGKOK TOWER 3, LEVEL 34 - 37, RAMA 4 ROAD, | LUMPHINI | PATHUM WAN | Bangkok | 10330 | +66 2264 0789-90 | Siriwan.Nitdamrong@th.ey.com · Title: 261 · Regis no: 5906 · Last name: NITDAMRONG · First name: SIRIWAN · Telephone: 02-264-9090 · Kamontip.Lertwitworatep@th.ey.com · Title: 261 · Regis no: 4377 · Last name: LERTWITWORATEP · First name: KAMONTIP · Telephone: 02-264-9090 · Sarinda.Hirunprasurtwutti@th.ey.com · Title: 262 · Regis no: 4799 · Last name: HIRUNPRASURTWUTTI · First name: SARINDA · Telephone: 02-264-9090 · somsak.chiratdhitiamphyvong@th.ey.com · Title: 260 · Regis no: 8874 · Last name: CHIRATDHITIAMPHYVONG · First name: SOMSAK · Telephone: 02-264-9090 | 9,410,000 | Y | Service | PPA Training | 450,000 | 450,000 | 0 |
Company Secretary and Other Assigned Persons
Company Secretary
| Title | First Name | Last Name | Telephone | |
|---|---|---|---|---|
| Ms. | Chompunuch | Meevang | chompunuch@interpharma.co.th | 02-634-0225 |
Chief Accountant
| Title | First Name | Last Name | Telephone | |
|---|---|---|---|---|
| Ms. | Supaporn | Chanwonggnam | pook.supaporn@interpharma.co.th | 02-634-0225 |
Head of Internal Audit
| Title | First Name | Last Name | Telephone | |
|---|---|---|---|---|
| Mr. | Supoj | Pannoi | pannoi_ten@amtaudit.com | 02-184-1846 |
Head of Compliance
| Title | First Name | Last Name | Telephone | |
|---|---|---|---|---|
| Ms. | Chompunuch | Meevang | chompunuch@interpharma.co.th | 02-634-0225 |
Investor Relations Contact
Does the Company Have an Investor Relations Contact?
Yes
Investor Relations Contacts
| Title | First Name | Last Name | Telephone | |
|---|---|---|---|---|
| Ms. | Chompunuch | Meevang | ir@interpharma.co.th | 02-634-0225 |
Representatives in Thailand (Foreign Companies)
Does the Company Have Representatives in Thailand?
No

